Picture loading failed.

Anti-TFPI therapeutic antibody (Pre-made Concizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Concizumab (mAb 2021) is a high-affinity, humanized, monoclonal IgG4 antibody (mAb) developed by Novo Nordisk A/S. It was directed against the Kunitz-2 domain of human tissue factor (TF) pathway inhibitor (TFPI), designed to target and selectively block the factor X (FX) a (FXa) binding site of TFPI.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-118-1mg 1mg 3090
GMP-Bios-ab-118-10mg 10mg 21890
GMP-Bios-ab-118-100mg 100mg 148000
GMP-Bios-ab-118-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-TFPI therapeutic antibody (Pre-made Concizumab biosimilar,Whole mAb)
INN Name Concizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure4dtg:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesNovo Nordisk
Conditions Approvedna
Conditions ActiveHaemophilia
Conditions Discontinuedna
Development Techna